| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Myristoylcholine chloride exerts its effects by interacting with cell membranes and altering their permeability. As a choline ester with a long-chain fatty acid, it can incorporate into lipid bilayers and modulate membrane properties. The compound's mechanism of action involves disruption of membrane integrity and modulation of membrane fluidity. It has been studied for its diverse biological activities, particularly in drug delivery systems and as a biosensor component. The compound's quaternary ammonium structure and lipophilic myristoyl chain allow it to interact with both hydrophobic and hydrophilic environments, making it valuable for membrane studies and drug delivery research.
|
|---|---|
| ln Vitro |
In vitro, myristoylcholine chloride is used as a biochemical reagent and organic compound for life science research. It exerts its effects by interacting with cell membranes and altering their permeability. The compound has garnered attention for its diverse biological activities, particularly in drug delivery systems and as a biosensor component. Cellular assays typically evaluate its membrane-disrupting effects, cytotoxicity, or its ability to enhance drug delivery. The compound's surfactant properties make it valuable for studying membrane biology and developing drug delivery systems.
|
| ln Vivo |
In vivo data for myristoylcholine chloride is limited, as it is primarily a research reagent. The compound is classified for research use only and is not intended for human or veterinary therapeutic applications. Its potential applications in drug delivery systems suggest that it may be used to enhance the absorption or distribution of therapeutic agents. The compound's membrane-disrupting activity would likely limit its systemic use. Specific in vivo data for the parent compound is not available in the public literature. The compound is not a therapeutic candidate.
|
| Enzyme Assay |
In vitro assays for myristoylcholine chloride typically evaluate its membrane-disrupting effects, surfactant properties, or cytotoxicity. A standard protocol involves incubating the compound with model membranes (liposomes) or cell cultures at varying concentrations. Membrane disruption is evaluated by measuring dye release from liposomes or changes in membrane permeability. Cytotoxicity is assessed using MTT or similar assays in mammalian cell lines. The compound is dissolved in water or buffer and diluted to working concentrations. IC₅₀ values are calculated from dose-response curves. The compound's surfactant properties require careful handling and appropriate controls.
|
| Cell Assay |
Cellular assays for myristoylcholine chloride typically evaluate its membrane effects or cytotoxicity. A standard protocol involves culturing mammalian cell lines in growth medium at 37°C with 5% CO₂. Cells are treated with varying concentrations of the compound for 24-72 hours. Cell viability is assessed using MTT, CCK-8, or similar assays. Membrane integrity is evaluated by measuring lactate dehydrogenase release or using fluorescent membrane permeability dyes. The compound's effects on drug delivery can be assessed by measuring the uptake of fluorescent or therapeutic agents. IC₅₀ values are calculated from dose-response curves.
|
| Animal Protocol |
In vivo animal studies for myristoylcholine chloride are not standard, as it is a research reagent rather than a therapeutic candidate. The compound is classified for research use only and is not intended for human or veterinary applications. Any animal studies would be limited to evaluating its potential as a drug delivery enhancer or its toxicological profile. The compound's membrane-disrupting activity suggests potential for irritation and toxicity. Specific in vivo protocols are not available in the public literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for myristoylcholine chloride is limited, as it is primarily a research reagent. The compound has a molecular weight of 349.98 g/mol and a molecular formula of C₁₉H₄₀ClNO₂. It appears as a white powder. As a quaternary ammonium compound with a long fatty acid chain, it is expected to have limited oral bioavailability and to be metabolized by esterases to myristic acid and choline. The compound is stored in a dry, cool place. Specific ADME data is not available.
|
| Toxicity/Toxicokinetics |
Myristoylcholine chloride is classified for research use only and is not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound should be stored in a dry, cool place away from incompatible materials. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values or detailed toxicological profiles are available in the public domain.
|
| Additional Infomation |
Myristoylcholine chloride (MChCl, Myr, CAS 4277-89-8) is a biochemical reagent with the molecular formula C₁₉H₄₀ClNO₂. It is a synthetic quaternary ammonium salt with a myristoyl fatty acid chain esterified to choline. The compound is used in membrane studies, drug delivery research, and as a biosensor component. It is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. It is available from multiple commercial suppliers in various pack sizes. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent.
|
| Molecular Formula |
C19H40CLNO2
|
|---|---|
| Molecular Weight |
349.98
|
| Exact Mass |
349.274
|
| CAS # |
4277-89-8
|
| PubChem CID |
77963
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
196 - 204°C (dec.) (lit.)
|
| LogP |
1.94
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
23
|
| Complexity |
259
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCC(=O)OCC[N+](C)(C)C.[Cl-]
|
| InChi Key |
CNJMYRYCYNAIOF-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C19H40NO2.ClH/c1-5-6-7-8-9-10-11-12-13-14-15-16-19(21)22-18-17-20(2,3)4;/h5-18H2,1-4H3;1H/q+1;/p-1
|
| Chemical Name |
trimethyl(2-tetradecanoyloxyethyl)azanium;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 125 mg/mL (357.16 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8573 mL | 14.2865 mL | 28.5731 mL | |
| 5 mM | 0.5715 mL | 2.8573 mL | 5.7146 mL | |
| 10 mM | 0.2857 mL | 1.4287 mL | 2.8573 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
